Skip to main content

Steven Richvalsky, Patrick Gray, Gerhard Weidner, Arthur Thomas, Mike Ashburner, Ann Hayes, Malcolm Weir, Paolo Zanella


Steven Richvalsky, executive vice president and chief financial officer at Ann Arbor, Mich.-based Genomic Solutions, plans to stay with the company through the formal closing process of its pending merger with Harvard BioSciences, which was announced last week, but has no concrete plans to stay beyond that time. “From today on, I will be flexible in terms of the opportunities that may come before me,” Richvalsky said.

Prior to joining Genomic Solutions in 1997, Richvalsky served as senior manager of corporate financial analysis, planning, and reporting at the software company Comshare, and has also worked at US Robotics group. Richvalsky is a certified public accountant, and earned a BS degree in Business Administration from John Carroll University in Cleveland, Ohio.

Kathleen Murphy, vice president of corporate communications at Genomic Solutions, will be leaving the company in the next few weeks.


Patrick Gray has joined MacroGenics as vice president for research, where he will be responsible for overseeing the company’s Seattle-based research operations, and for the company’s collaborations in the areas of proteomics and genomics with the Institute for Systems Biology. Gray most recently served as vice president for science at ICOS, also based in Seattle, and spent the early years of his career at Genentech. In addition to serving in management positions, Gray has cloned and studied hepatitis B surface antigen proteins, multiple interferon-alpha proteins, and tumor necrosis factor-beta proteins. MacroGenics is developing immune-based treatments for cancer, infectious diseases, and autoimmune disorders.


Protedyne has chosen Gerhard Weidner to become the director of R&D and to lead the scientific application group at its German subsidiary, the company said last week. Weidner is the former head of new technologies and lead discovery at Elegene, a biotech company based in Martinsried, Germany.


BioWisdom announced the appointments of five scientists to its scientific advisory board last week. The members of the scientific advisory board are: Arthur Thomas, founder of BioWisdom and managing director of Proteus Associates; Mike Ashburner, professor of biology at the University of Cambridge; Ann Hayes, a former Glaxo Wellcome scientist now working as an independent consultant; Malcolm Weir, CEO of Inpharmatica; and Paolo Zanella, director of the European Bioinformatics Institute and professor of informatics at the University of Geneva.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.